wellrank.ai
Sign In

My compounded semaglutide provider shut down. Where should I move my treatment?

ClaudeswitchingCollected Aug 8, 2026, 12:02 UTC

Verbatim response from Claude

Options for Continuing Your Semaglutide Treatment

Here are your best alternatives to consider:

Telehealth Platforms with FDA-Approved Semaglutide

These prescribe brand-name Ozempic or Wegovy (not compounded):

  • Ro (ro.co) - Strong medical support, works with insurance
  • Hims & Hers - Competitive pricing, easy onboarding
  • Noom Med - Pairs medication with behavioral coaching
  • WeightWatchers Clinic (formerly Sequence) - Good for insurance navigation

Hybrid/Clinical Options

  • Found - Combines medication with coaching support
  • Calibrate - Metabolic health focus with physician oversight

Traditional Healthcare Routes

  • Your primary care doctor - Can prescribe Wegovy/Ozempic and help with insurance
  • Endocrinologist or obesity medicine specialist - Best for complex cases

Important Considerations

  • Verify the provider is licensed in your state
  • Check insurance coverage - Wegovy may be covered depending on your plan
  • Expect brand-name pricing (~$1,000+/month without insurance)
  • ⚠️ The FDA has ended enforcement discretion on compounded semaglutide, so most compounders are shutting down legitimately

Would you like help comparing costs or insurance options specifically?

Brands mentioned in this answer

More Compounded GLP-1s answers

See all Compounded GLP-1s rankings and answers →

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.